No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques by Williams, Dhanya K et al.
No Evidence of Xenotropic Murine Leukemia Virus-Related Virus
Transmission by Blood Transfusion from Infected Rhesus Macaques
Dhanya K. Williams,a Teresa A. Galvin,a Yamei Gao,b Christina O’Neill,a* Dustin Glasner,a Arifa S. Khana
Laboratory of Retroviruses,a Laboratory of Respiratory Viral Diseases,b Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug
Administration, Bethesda, Maryland, USA
The discovery of xenotropic murine leukemia virus-related virus (XMRV) in human tissue samples has been shown to be due to
virus contamination with a recombinant murine retrovirus. However, due to the unknown pathogenicity of this novel retrovirus
and its broad host range, including human cell lines, it is important to understand the modes of virus transmission and develop
mitigation and management strategies to reduce the risk of human exposure and infection. XMRV transmission was evaluated
by whole-blood transfusion in rhesus macaques. Monkeys were infected with XMRV to serve as donor monkeys for blood trans-
fers at weeks 1, 2, and 3 into naïve animals. The donor and recipient monkeys were evaluated for XMRV infection by nested PCR
assays with nucleotide sequence confirmation, Western blot assays for development of virus-specific antibodies, and coculture of
monkey peripheral blood mononuclear cells (PBMCs) with a sensitive target cell line for virus isolation. XMRV infection was
demonstrated in the virus-injected donor monkeys, but there was no evidence of virus transmission by whole-blood transfusion
to naïve monkeys based upon PCR analysis of PBMCs using XMRV-specific gag and env primers, Western blot analysis of mon-
key plasma up to 31 to 32 weeks after transfusion, and coculture studies using monkey PBMCs from various times after transfu-
sion. The study demonstrates the lack of XMRV transmission by whole-blood transfusion during the acute phase of infection.
Furthermore, analysis of PBMC viral DNA showed extensive APOBEC-mediated G-to-A hypermutation in a donor animal at
week 9, corroborating previous results using macaques and supporting the possible restriction of XMRV replication in humans
by a similar mechanism.
The initial discovery of xenotropic murine leukemia virus-re-lated virus (XMRV) in human prostate cancer tissue (1), and
later in some peripheral blood mononuclear cell (PBMC) samples
from patients with myalgic encephalomyelitis/chronic fatigue
syndrome (2), raised public health concerns related to the discov-
ery of a novel human retrovirus and potential virus transmission
due to exposure to mice (3) and infected blood donors and blood-
derived products (4–11). These emerging concerns led to inten-
sive discussions and investigations of XMRV, including molecular
and biological characterization of the virus and the development
of assays, standards, and nonhuman primate (NHP) models for
further studies of human infection and disease association. The
results of several studies evaluating XMRV infection in humans
indicated that the results of the original reports were due to sample
and/or laboratory contaminations (12–19). Furthermore, XMRV
was found at high titers in the 22Rv1 human prostate cancer cell
line (20) and was recently shown to have most likely originated
from recombination between two different endogenous murine
retrovirus sequences during derivation of the 22Rv1 human pros-
tate cancer cell line by serial passage of a human prostate tumor
xenograft in nude mice (21, 22). These findings have led to the
general scientific consensus that XMRV is not a human retrovirus
but a novel recombinant murine retrovirus with some unique
biological properties (23). XMRV has a broad host range and can
infect a variety of human cell lines in vitro (24–27) and nonhuman
primate cells and tissues in vivo (5, 28). Studies of XMRV injection
in rhesus macaques and pigtailed macaques along with a study of
wild-derived Mus pahari mice (29) indicated that XMRV infec-
tion shows a transient acute phase of infection, during which time
the virus was detected in peripheral blood cells. After this phase,
however, the virus could not be detected in the blood but persisted
at low levels in various host tissues. Additionally, a low level of
vertical transmission was shown in the mouse study (30).
An important aspect of biological products is to demonstrate
the absence of unintended viruses and to determine the risk of
human infection and virus transmission in case of inadvertent
exposure and infection. Due to the undefined pathogenic poten-
tial of XMRV, the unexpected discovery of the virus or its se-
quences in some cell lines used broadly in research, and broad
contamination of laboratory reagents with murine leukemia virus
(MLV)-related sequences, it is prudent to evaluate the presence of
XMRV in biological materials used for manufacturing of products
for human use. XMRV has been investigated and was shown to be
absent in live-virus vaccines (31), and we previously developed
sensitive PCR assays and demonstrated the absence of XMRV-
specific sequences in a variety of cell lines, including some related
to vaccine cell substrates (32). In this study, we have used the
rhesus macaque model to evaluate the modes of XMRV transmis-
sion by investigating virus infection and replication after direct
virus injection or blood transfusion from infected monkeys.
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XMRV stock. XMRV stock was prepared by transfection of LNCaP cells
(human prostate carcinoma cell line; ATCC CRL-1740, clone FGC) with
VP62/pcDNA3.1 (contributed by R. H. Silverman and B. Dong and ob-
tained from the NIAID AIDS Repository), using Lipofectamine 2000 (cat-
alogue no. 11668-019; Invitrogen, Carlsbad, CA). Briefly, 500 l RPMI
1640 medium (catalogue no. 112-024-101; Quality Biologicals) contain-
ing 5g DNA was combined with 500l RPMI 1640 medium (containing
20 l Lipofectamine 2000 and incubated for 15 min at room temperature
before being added to LNCaP cells [400,000 cells, which were planted 24 h
prior to transfection in a 25-cm2 flask]). After 16 h of incubation at 37°C,
RPMI 1640 medium was changed to RPMI 1640 complete medium (sup-
plemented with 10% fetal bovine serum [FBS], heat inactivated at 56°C
for 30 min [catalogue no. SH30071.03; HyClone, Logan, UT]; 2 mM L-
glutamine; 1 mM sodium pyruvate; 10 mM HEPES [catalogue no. 15630-
080; Invitrogen, Carlsbad, CA]; 250 U of penicillin per ml; and 250 g of
streptomycin per ml). Cells were transferred into a 75-cm2 flask on day 3
and then into a 150-cm2 flask on day 19. Cells were passaged at a subcul-
tivation ratio of 1:3 every 4 days upon reaching confluence using 0.05%
trypsin– 0.53 mM EDTA (catalogue no. 25300-054; Invitrogen). Medium
was changed on day 29 and reduced from 40 ml to 25 ml for preparation
of the virus stock on day 30 by pooling and filtering the supernatant
(0.45-m filter; Corning) and storing aliquots of the XMRV stock at
80°C. Virus production in the supernatant was determined using the
single-tube fluorescent product-enhanced reverse transcriptase (RT)
(STF-PERT) assay (33). Cells at day 34 were collected along with unin-
fected control cells and prepared for transmission electron microscopy
(TEM) analysis, as previously described (34). The XMRV stock titer (50%
tissue culture infective dose [TCID50] endpoint) was determined in
LNCaP cells and in Mv1Lu cells (mink lung; ATCC CCL-64) using 10-fold
serial dilutions and evaluation of the PERT activity in filtered superna-
tants collected at day 7. The TCID50 was calculated by the Karber method
(35). Mv1Lu cells were grown in Eagle’s minimum essential medium
(modified) with Earl’s salt without L-glutamine (catalogue no. 15-010-
CV; Mediatech, Manassas, VA) containing 10% FBS, 2 mM L-glutamine,
100 U of penicillin per ml, and 100 g of streptomycin per ml with 1
nonessential amino acids (MEM-NEAA, 100; Quality Biological, Inc.,
Gaithersburg, MD) and 1 mM sodium pyruvate (designated complete
EMEM). Additionally, virus focus-forming units (FFU) per ml were de-
termined by a mink S L assay (BioReliance).
Monkey injections and blood transfusions. The source of the ani-
mals, retrovirus screening, and maintenance of rhesus macaques (Macaca
mulatta) at the FDA animal facility (National Institutes of Health, Be-
thesda, MD) were previously described (36). The animals, designated
DBL2, DBNP, DBHH, DBHE, DBLZ, DBCF, and DBHT, were adults at
the time of this study and had previously tested negative for type D simian
retrovirus (SRV), simian T-cell lymphotropic virus (STLV), and simian
immunodeficiency virus (SIV) based upon serology and further tested
negative for SRV based upon a PCR assay and virus isolation. All animals
were positive for simian foamy virus (SFV) by a virus-specific, nested PCR
assay described previously (34), except animals DBL2 and DBHE, which
were negative based upon a PCR assay and by a lack of virus isolation using
monkey PBMCs in a coculture assay. Prior to the testing and subse-
quently, the animals were housed in single cages and handled with special
precautions to avoid cross-contamination. Rhesus macaque CF86 was
added during the course of the study and was SFV positive. All animals
were maintained in accordance with the Guide for the Care and Use of
Laboratory Animals under an approved protocol by the Institute Animal
Care and Use Committee (37).
Monkeys were injected with XMRV intravenously (saphenous vein) to
serve as donor animals for whole-blood transfusion studies or with me-
dium as a control. For ease of monkey identification in this paper, blood
donor animals are indicated with a “(d)” after their designation, blood
recipient animals are indicated with an “(r),” and the control animal is
indicated with a “(c).” Animals DBL2(d) and DBNP(d) were injected with
XMRV stock (1 ml), and animal DBCF(d) was injected with 1 ml of
resuspended and pooled virus pellets after ultracentrifugation to remove
spent medium (four 1-ml aliquots of the virus stock were ultracentrifuged
through 1 ml of 20% sucrose in phosphate-buffered saline [PBS] [pH 7.4]
[Quality Biologicals] at 36,000 rpm for 2 h at 4°C using a Beckman TLA45
rotor; each tube was resuspended in 350 l of complete RPMI medium
and pooled). As a control, animal DBHH(c) was injected with complete
medium.
Blood (10 ml) was collected in heparin from animals DBL2(d) and
from animal DBNP(d) at week 1 after XMRV injection and transfused
into animals DBHE(r) and DBLZ(r), respectively. Blood (10 ml) collected
in heparin from animal DBCF(d) was transfused at week 2 and week 3
after XMRV injection into animals DBHT(r) and CF86(r), respectively.
This is shown schematically in Fig. 2. Blood transfer, collections, and
preparation of PBMCs were done as previously described (36).
Blood was collected into EDTA Vacutainer tubes (BD) to prepare
PBMCs and plasma, and aliquots were stored in liquid nitrogen and at
80°C, respectively.
Western blot analysis. Cell lysates were prepared from uninfected
mink cells and XMRV-infected mink cells as described previously (34).
Protein concentration was determined with a protein assay dye (Bio-Rad,
Hercules, CA). One hundred twenty micrograms of uninfected or XMRV-
infected mink cell lysate was analyzed on a 12% Tris-glycine gel, run for
1.5 h at 125 V (Novex X-cell II system; Novex, San Diego, CA) separately
in single-well gels in 1 Tris-glycine running buffer (24.8 mM Tris, 192
mM glycine, 0.1% sodium dodecyl sulfate). Proteins on the gel were trans-
ferred onto a nitrocellulose membrane for 1 h at 30 V in a separate appa-
ratus in a solution containing 24.8 mM Tris, 192 mM glycine, and 20%
methanol. The membrane was rinsed in transfer buffer and cut into twelve
5-mm strips. The strips were placed protein side up into individual wells
of a plastic tray, rinsed at room temperature for 5 min in 5 ml of ultrapure
water and PBS without Ca2 and Mg2, and then blocked overnight on a
shaker at 4°C in PBS (pH 7.3)– 0.05% Tween (PBST) containing 5% non-
fat dried milk (PBST5%). The strips were incubated at room tempera-
ture on a shaker for 4 h. Strips were then incubated with a 1:100 dilution
of monkey plasma in PBST5% for 2 h at room temperature and then
overnight at 4°C on a shaker. Strips were brought to room temperature,
and unbound antibody was washed three times for 5 min in PBST5%
using approximately 5 ml per strip.
Horseradish peroxidase (HRP)-labeled goat anti-monkey IgG (cata-
logue no. 074-11-021; Kirkegaard & Perry Laboratories Inc., Gaithers-
burg, MD) was used as a secondary antibody. Strips were incubated in 2
ml each of a 1:40,000 dilution of secondary antibody in PBST5%, in all
cases except for animal DBLZ(r), where a 1:20,000 dilution was used due
to low signal, for 2 h on a shaker at room temperature. Strips were then
washed four times for 10 min in PBST and once in PBS without Ca2 and
Mg2 for 30 min, using approximately 5 ml of solution per strip.
The protein bands were visualized by chemiluminescence with a sub-
strate system (SuperSignal West Pico chemiluminescent substrate; Pierce,
Rockford, IL) on a shaker using 2 ml of substrate per filter for 2 min and
then blotted with paper (Whatman 3MM; Whatman plc, Maidstone,
Kent, England) to remove excess substrate and exposed for various times
ranging from 1 s to 6 min using BioMax film (BioMax MR film; Kodak,
Rochester, NY).
Infectivity studies. Monkey PBMCs (4 106 to 5 106 PBMCs) were
stimulated with phytohemagglutinin (PHA; catalogue no. HA16; Remel,
Inc., Lenexa, KS), as previously described (36, 38), for 72 h in a 25-cm2
flask prior to coculture with Mv1Lu cells (400,000 cells that were pre-
planted for 2 h in a 25-cm2 flask for attachment) in complete EMEM for at
least 30 days or until extensive cell lysis occurred due to the cytopathic
effect (CPE) of SFV, which was present in some monkeys prior to the
study. PBMCs were fed back to the Mv1Lu cells for the initial 3 passages to
provide an extended coculture of the PBMCs with the target cells and
possibly enhance virus isolation. DNA was prepared from the cells at
various times after coculture for PCR analysis. XMRV identity was con-
No XMRV Transmission by Blood Transfusion in Monkeys
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firmed by nucleotide sequence analysis of PCR-amplified fragments. Cell
pellets were also prepared for TEM analysis.
Sensitivity of XMRV detection in Mv1Lu cells was determined using
10-fold serial dilutions of the virus stock. Infections were set up by over-
night incubation in complete medium containing 4 g/ml Polybrene
(catalogue number TR-1003-G; Millipore, Billerica, MA), after which
cells were propagated in complete medium. Cell pellets (2  106 cells)
were collected at each passage, and DNA was prepared according to the
manufacturer’s protocol, except that a 10-min incubation at 95°C was
added following the proteinase K incubation step (QiaAmp DNA blood
minikit; Qiagen, Valencia, CA). Virus replication was evaluated by PCR
analysis of 0.67g DNA, calculated based upon 6.6 pg DNA per cell, using
XMRV gag and env outer and inner primer pairs. The results were ob-
tained by electrophoresis on a 1.4% agarose gel with UV visualization of
ethidium bromide-stained DNA.
PCR assays. Total DNA was prepared directly from whole blood using
the QiaAmp DNA blood minikit (Qiagen) as described above or from
PBMCs as previously described (36) for PCR analysis. XMRV PCR prim-
ers and assays conditions for amplification of gag and env sequences using
outer and inner primers were previously described, with an annealing
temperature of 63°C used for the outer primers (32). Detection was based
upon UV visualization of amplified fragments in an ethidium bromide-
stained gel. The sensitivity of the XMRV PCR assays was determined to be
10 copies in approximately 1.8 105 cells, equivalent of human DNA.
SFV long terminal repeat (LTR) outer primers were used as previously
described (36). Human -actin primers were used to amplify an 838-bp
fragment as a control for the presence of DNA in the sample (Clontech,
Mountain View, CA). The forward primer sequence was 5=-ATCTGGCA
CCACACCTTCTACAATGAGCTGCG-3=, and the reverse primer se-
quence was 5=-CGTCATACTCCTGCTTGCTGATCCACATCTGC-3=.
Thermal cycling conditions were 95°C for 3 min followed by 35 cycles of
95°C for 30 s, 60°C for 1 min, and 72°C for 1 min. Fragment sizes were
determined using a 100-bp ladder (New England BioLabs, Ipswich, MA).
PCR without DNA was used as a negative control.
DNA cloning and sequencing. For direct sequencing of DNA, PCR-
amplified fragments were treated with ExoSAP-IT (Affymetrix, Santa
Clara, CA), and nucleotide sequences were determined with PCR primers
by using an Applied Biosystems 3130xl Genetic Analyzer according to the
manufacturer’s standard protocol (Applied Biosystems, Foster City, CA).
Sequence alignment was done using Vector NTI software (Invitrogen,
Carlsbad, CA). For single-copy sequencing, PCR-amplified DNA frag-
ments were gel purified using the Zymoclean gel DNA recovery kit (Zymo
Research Corporation, Irvine, CA) and cloned by ligation into the
pGEM-T Easy vector (Promega Corporation, Madison, WI), according to
manufacturer’s instructions. Ten colonies were selected from each trans-
formation for DNA preparation using the QIAprep Spin Miniprep kit
(Qiagen), and nucleotide sequences were obtained with vector-specific
SP6 and T7 primers using the ABI 3130xl Genetic Analyzer. Sequence
alignment was done using Vector NTI with XMRV VP62, the inoculating
virus, as a reference sequence (GenBank accession no. EF185282).
RESULTS
XMRV infection in rhesus macaques. A well-characterized
XMRV stock was prepared by transfection of LNCaP cells with
cloned VP62/pcDNA3.1 DNA. XMRV production in the cells was
visualized by TEM (Fig. 1), the amount of virus in the stock was
quantified for the total number of particles by using an STF-PERT
assay, and infectious particles were determined as TCID50 in
LNCaP cells and Mv1Lu cells. The total number of RT-containing
particles determined by the STF-PERT assay was 5.5 106 parti-
cles per ml; the infectious particles were determined by virus titra-
tion using the STF-PERT assay for readout (105.5 TCID50 per ml in
Mv1Lu cells and 104.5 TCID50 per ml in LNCaP cells) or focus
formation in S L mink cells (1.04  104 FFU per ml). These
results indicated that the ratio of noninfectious to infectious par-
ticles was about 10:1 or 100:1, which is the expected range for
gammaretroviruses and therefore suitable for use in further stud-
ies. Additionally, Mv1Lu cells were found to be 10-fold more sen-
sitive for XMRV replication than LNCaP cells and were a better
target cell line for virus detection and isolation.
Two studies were done to evaluate infection of rhesus ma-
caques with XMRV (outlined in Fig. 2). Initially, 1 ml of virus
stock was used to inject animals DBL2(d) and DBNP(d), and 1 ml
complete medium was injected into animal DBHH(c) as a control.
The inoculum titer (determined as 104.5 TCID50 per ml in LNCaP
cells or 105.5 TCID50 per ml in Mv1Lu cells) was based upon our
previous study in rhesus macaques with a recombinant ampho-
tropic murine leukemia retrovirus that resulted in a productive
infection with establishment of long-term persistence (our un-
published data) and with SFV (38). Nested PCR analysis of DNAs
prepared from whole blood or PBMCs of animal DBL2(d) at
FIG 1 TEM analysis of XMRV-infected cells used for preparation of virus stock. Control LNCaP cells (A) and XMRV-infected LNCaP cells (B) are shown. The
boxed area in panel B is enlarged in the inset.
Williams et al.





ber 2, 2014 by W






weeks 0, 1, 2, 3, 4, 5, 6, 8, and 10 indicated transient detection of
XMRV from weeks 2 through 8 using gag and/or env primers (data
not shown). Development of XMRV-specific antibodies against
p30CA was seen at week 8 and persisted at 59 weeks. The detection
of antibodies against gp70SU was difficult to interpret due to sim-
ilar-sized bands being detected in the cell lysate; therefore, the
results of antibodies developed against Env were based upon p15E
(Fig. 3A). PCR analysis of animal DBNP(d) indicated transient
detection of XMRV-specific gag and/or env sequences from weeks
2 through 10 (data not shown), and virus-specific antibodies to
Gag and Env were seen at week 6 and persisted at week 59
(Fig. 3B).
In the second study, in an effort to generate a more robust in
vivo infection, the virus stock was subjected to ultracentrifugation
to remove any potential inhibitory or interfering factors in the
spent medium, and the resuspended pellet (about 4 concen-
trated) was injected into a naïve monkey, animal DBCF(d). West-
ern blot analysis indicated detection of Gag (p30CA) and Env
(p15E) antibodies at week 6 with increasing intensity up to week
41 (last time point tested) (Fig. 3C). Although Western blot anal-
ysis is not quantitative, the response seemed to be stronger in
animal DBCF(d) than in animal DBL2(d) or DBNP(d), which
were injected with the XMRV stock, without prior ultracentrifu-
gation. Nested PCR analysis of DNAs prepared from whole blood
or PBMCs indicated amplification of fragments of the expected
size with gag and env primers at weeks 1 to 9 and week 13; a faint
band was seen at week 15 with env primers (Fig. 4). In some cases
when the initial nested PCR results were negative, positive results
were seen when samples were tested in an additional four repli-
cates (indicated by asterisks in Fig. 4 and details described in the
legend). Negative results were obtained at weeks 11, 15, 41, and 56
in all five replicates.
Evaluation of XMRV transmission by whole-blood transfu-
sion. Initially, based upon previously reported results for the ki-
FIG 2 Schematic of monkey injections and blood transfusions. Monkeys were
injected with XMRV filtered supernatant virus stock (A) or with pelleted virus
resuspended in PBS (pH 7.4) (B).
FIG 3 Detection of XMRV-specific antibodies in donor monkeys by Western blotting. Plasma samples, obtained on the day of injection (week 0) and at various
weeks following inoculation, were incubated with a nitrocellulose membrane containing lysate prepared from XMRV-infected Mv1Lu cells, and proteins were
visualized as described in Materials and Methods. An exposure of chemiluminescence film is shown. The XMRV-specific Gag p30CA and Env p15E proteins are
indicated based upon standard markers (MultiMark; Novex, San Diego, CA).
FIG 4 PCR analysis of XMRV infection in animal DBCF(d). Nested gag and env
PCR assays were done on monkey blood (weeks 2 and 3) and PBMC DNAs. Blood
from week 0 was collected prior to virus injection. Ten microliters of sample was
used for the first PCR with gag and envprimers and for the-actin PCR assay. The
positive () control was 10 copies of XMRV cloned DNA spiked in a background
of 0.5g human cellular DNA. Sizes of the expected PCR-amplified fragments are
indicated. Asterisks in the lanes indicate the number of positive PCRs out of 5
replicates (, 4 out of 5; , 3 out of 5; , 1 out of 5).
No XMRV Transmission by Blood Transfusion in Monkeys





ber 2, 2014 by W






netics of XMRV infection in rhesus monkeys (28), whole blood
was transfused at week 1 after virus injection from animals
DBL2(d) and DBNP(d) into animals DBHE(r) and DBLZ(r), re-
spectively (Fig. 2). Subsequent analysis of monkey PBMC DNAs
by nested PCR assays indicated that week 1 donor samples were
virus negative, whereas virus was detected transiently from weeks
2 through 8 (data not shown). Additionally, no virus was isolated
from PBMCs of animal DBL2(d) 1 week after XMRV injection,
based upon nested PCR analysis of DNAs prepared from target
cells at day 30 after coculture; mouse -actin primers amplified
the expected 340-bp fragment, indicating the presence of intact
DNA in the test samples (data not shown). Similarly, negative
results for XMRV isolation were obtained in coculture studies
with week 1 PBMCs from animal DBNP(d); however, since the
monkey was SFV positive prior to XMRV infection, SFV isolation
was demonstrated by using an SFV-specific PCR assay at day 25
after coculture of week 0 and week 1 PBMCs of animal DBNP(d)
(data not shown).
Although there was no evidence of XMRV infection in PBMCs
of animals DBL2(d) and DBNP(d) at week 1 after virus infection,
blood recipient animals DBHE(r) and DBLZ(r) were analyzed for
virus transmission in case there was a low level of undetected
infection in the PBMCs or virus in the plasma of the donor mon-
keys. DNAs prepared directly from whole blood or PBMCs at
weeks 0, 1, 2, 3, 4, 5, 6, and 9 were negative by nested PCR assays
for XMRV gag and env, and the monkeys were negative for the
development of XMRV-specific antibodies from week 0 through
week 32 (last time point tested) by Western blotting.
To further evaluate XMRV transmission, blood from animal
DBCF(d) (injected with 4 resuspended virus) was transfused at
week 2 and week 3 after XMRV injection into animals DBHT(r)
and CF86(r), respectively. Subsequent PCR analysis indicated that
PBMC DNA from animal DBCF(d) DNA from these time points
was positive for XMRV gag and env (Fig. 4).
The sensitivity of XMRV isolation was evaluated by coculture
of PBMCs with Mv1Lu cells followed by detection using PCR
assays. Analysis of a 10-fold dilution series of XMRV stock indi-
cated that 1 TCID50 could be detected by nested PCR using gag
and env nested primers at day 9 after infection of Mv1Lu cells (Fig.
5A). XMRV-specific gag and env DNA fragments amplified using
nested PCR from infection with 1 TCID50 were confirmed by nu-
cleotide sequencing (data not shown).
XMRV was isolated from cocultures at days 19 to 34 using
animal DBCF(d) PBMCs from weeks 1, 3, and 4 after XMRV
injection. PCR analysis detected gag sequences after the first round
of PCR; no fragments were amplified from the week 0 or the neg-
ative-control sample using nested PCR (Fig. 5B). There were in-
sufficient PBMCs available from week 2 for the coculture assay.
FIG 5 PCR analysis of mink cells cocultured with monkey PBMCs. (A) Serial dilutions of XMRV stock were used to determine the sensitivity of virus detection
in Mv1Lu cells. PCR analysis of Mv1Lu cells at day 9 after infection is shown, using gag and env outer and inner primer sets. Arrows indicate the size of the
expected XMRV-specific fragment. Lanes 1 to 7, XMRV TCID50 determined in Mv1Lu cells; M, 1-kb marker; con, uninfected-cell DNA;, no-DNA control for
PCR. Monkey PBMCs (5 106) were PHA stimulated and cocultured with Mv1Lu cells (400,000 cells), as described in Materials and Methods. (B and C) DNA
was prepared from cell pellets obtained at the end of the culture period or upon extensive CPE due to the presence of SFV in the monkey PBMCs, at days 19 to
34 in the case of donor monkey DBCF(d) (B) and at days 16 to 30 and 25 to 30 in the case of blood recipient monkeys DBHT(r) and CF86(r), respectively (C).
Results from outer PCR primers or nested PCR analysis for XMRV gag and env as well as for SFV LTR using outer primers are shown. Expected sizes of
PCR-amplified fragments are shown based upon the positive control DNAs (lane) from XMRV-infected or SFV-infected cells; uninfected DNA is the negative
control (lane). Weeks of isolation of PBMCs used for coculture are indicated. PCR-amplified fragments of SFV at week 0 from animals CF86(r) and DBHT(r)
and at week 1 from animal DBCF(d) were sequenced. Additionally, the PCR-amplified fragment of XMRV from week 1 from animal DBCF(d) was sequenced.
Williams et al.
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SFV LTR sequences were amplified using outer primers from
week 0 in addition to weeks 1, 3, and 4, thus confirming SFV
infection in the monkey prior to study initiation. The identity of
the XMRV and SFV PCR-amplified fragments was confirmed by
nucleotide sequence analysis of the fragments amplified from
week 1 PBMC coculture DNA.
Evaluation of animals DBHT(r) and CF86(r), which were
transfused with blood from animal DBCF(d), indicated that both
blood recipient animals were negative for XMRV infection by
nested gag and env PCR analysis of PBMC DNAs prepared from
animals DBHT(r) and CF86(r) at weeks 6, 7, 8, and 9 and at weeks
5, 6, 7, and 8, respectively; additionally, there was no detection of
XMRV-specific antibodies up to 32 weeks in the case of animal
DBHT(r) and up to 31 weeks in the case of animal CF86(r) (data
not shown). To further confirm the absence of XMRV transmis-
sion, monkey PBMCs were cocultured with Mv1Lu cells at various
times after transfusion. The results of PCR analysis of DNAs pre-
pared from PBMC coculture studies of animal DBHT(r) at days 16
to 30 postcoculture and from animal CF86(r) at days 25 to 30
postcoculture are shown in Fig. 5C: there was no detection of
XMRV sequences using nested PCR for gag in either monkey. The
amplification of SFV LTR sequences from all of the test samples
demonstrated the presence of intact DNA in the samples and pro-
vided a relevant positive control for virus isolation by coculture of
monkey PBMCs. The identity of the SFV fragment amplified from
the week 0 sample was confirmed by sequencing. The control sam-
ples gave the expected negative and positive results.
Sequence analysis of XMRV infection in vivo. XMRV infec-
tion in PBMC DNA was seen by nested PCR assays for animal
DBCF(d) until week 9 after virus injection and then reappeared at
week 13, before becoming undetectable after week 15 with both
gag and env primers. In some cases, a positive result was detected
only after testing replicates, which suggested changes in the PBMC
viral load during the course of virus infection in the animal. Anal-
yses of XMRV infection in rhesus and pigtailed macaques previ-
ously showed that virus replication seems to be restricted due to
APOBEC-mediated G-to-A hypermutation (40, 41). Our analysis
of PCR-amplified fragments from PBMC DNAs in gag for weeks 1,
7, 9, and 13 indicated a few, mostly single-nucleotide changes in
the region of gag analysis that did not evolve further over time
(data not shown). However, analysis of env for weeks 5, 6, 7, 9, and
13 indicated significant sequence changes at week 9, which con-
sisted of multiple G-to-A mutations as well as base deletions and
insertions. The majority of these changes were also seen at week
13, along with additional mutations and some reversions. The
results of the nucleotide sequence analysis indicated that most of
the changes seen in env were G-to-A mutations and occurred
within GG and GA dinucleotides (Fig. 6).
DISCUSSION
The discovery of XMRV as a novel human retrovirus in samples
from patients with prostate cancer (1) and chronic fatigue syn-
drome (2) generated great excitement and debate as well as skep-
ticism (42) regarding the causal relationship of a novel retrovirus
with these diseases; however, there were also heightened public
health safety concerns related to the lack of knowledge regarding
virus transmission and infection in humans. In this study, we
demonstrated the lack of XMRV transmission in rhesus macaques
that received a whole-blood transfusion from virus-infected do-
nor monkeys during the acute phase of infection. The transfused
monkeys tested negative up to 32 weeks after transfusion based
upon PCR analysis of PBMC DNA, Western blot analysis, and
virus isolation.
XMRV infection was seen in the donor monkeys by direct in-
jection of the virus stock, and the infection seemed enhanced in
animal DBCF(d) after injection with a concentrated (4) virus
stock based upon the stronger antibody responses and detection
of virus sequences in the PBMCs by PCR assays. This may be due
to the removal of spent culture medium that may have contained
inhibitory factors or the concentration of virus by ultracentrifu-
gation. Similarly, a robust response was seen previously by On-
lamoon et al. upon reinfection of rhesus monkeys using the same
inoculum titer after ultracentrifugation through sucrose (28). Re-
gardless, XMRV infection in monkeys is restricted, since robust
infection could not be established even after using ultracentri-
fuged virus. APOBEC3-mediated restriction of XMRV replication
has been shown in human cell lines (41, 43, 44) and in monkeys
(40, 41). Our study also showed an extensive accumulation of
G-to-A mutations and other nucleotide changes in PBMC viral
DNA from week 9 in animal DBCF(d), thus corroborating the role
of APOBEC3 proteins in limiting XMRV infection in monkeys.
Interestingly, in contrast to the results reported previously by
Zhang et al., where most of the G-to-A mutations occurred in the
context of GA and GC dinucleotides (41), the majority of muta-
tions seen in our analysis involved GG and GA dinucleotides,
which is characteristic of APOBEC3G activity in human immuno-
deficiency virus type 1 (HIV-1) mutations in human PBMCs (45,
46) Thus, it is expected that such APOBEC3-mediated hypermu-
tations would reduce the risk of a productive infection in humans
in the case of an inadvertent virus infection. The lack of efficient
virus replication in monkeys may also contribute to the lack of
XMRV transmission by blood transfusion. Although neutralizing
antibodies can contribute to the lack of retrovirus infection (47,
48) and transmission (38), and they were shown to be present as
early as week 2 in a pigtailed macaque study after XMRV injection
(40), these were not likely to be involved in the lack of XMRV
transmission in this study, since similar results were obtained by
blood transfusions at week 1, week 2, and week 3.
The results of XMRV studies in macaques seem similar to those
with a replication-competent, recombinant amphotropic murine
retrovirus generated from a Moloney MLV (MoMLV)-based gene
therapy packaging cell line, where large amounts of virus estab-
lished only transient infection and were “cleared” from the pe-
ripheral blood after intravenous injection in normal, immuno-
competent animals or a moderately immune-suppressed monkey
(49, 50). However, injection of highly immunosuppressed mon-
keys with a similar recombinant murine retrovirus containing
amphotropic env sequences resulted in high retrovirus replication
and T cell lymphomas in 3 animals after retrovirus-mediated gene
transfer (39). XMRV injection showed increasing virus-specific
antibody responses in donor monkeys to about 39 weeks, indicat-
ing virus replication in vivo, whereas in previous studies, re-
sponses declined after 16 weeks (28, 40). Although no clinical
signs were seen at about 2 years postinfection based upon physical
examination, blood chemistry, and complete blood count (CBC)
differential, consistent with data from other macaque studies (28,
40), the generation of leukemias with a murine retrovirus under
immunosuppressed conditions in monkeys emphasizes the need
for caution regarding XMRV exposure in humans.
Previous studies have shown that MLV-related sequences were
No XMRV Transmission by Blood Transfusion in Monkeys
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FIG 6 Nucleotide sequence analysis of XMRV in PBMC DNA from animal DBCF(d). Nucleotide sequences in env were obtained directly from PCR-amplified
fragments in the case of weeks 5, 6, and 7 or after DNA cloning in the case of weeks 9 and 13. Sequences were compared with the analogous region in XMRV VP62;
identical bases are indicated by a dot, different bases are shown, and absent nucleotides are indicated by a dash. The nucleotide base numbers are indicated based
upon the XMRV VP62 genome (GenBank accession no. EF185282). The numbers in parentheses indicate the number of identical cloned DNAs.
Williams et al.
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a contaminant in some widely used laboratory reagents (14–16,
19, 51) and also in the research samples that were used for the
initial discovery of XMRV (1). The biological properties of XMRV
indicate a broad host range and cell tropism, including human cell
lines (26, 27, 52), and XMRV contamination was found in several
cell lines used for research (52). These results emphasize the need
to evaluate XMRV and other MLV contaminations in cell lines
used in the laboratory and in the manufacture of biological prod-
ucts (32) as well as to minimize virus exposure to reduce the po-
tential risk of human infection.
XMRV was discovered in prostate cancer tissue using a Viro-
chip DNA microarray (1). Broad nucleic acid-based virus detec-
tion technologies such as virus microarrays, massively parallel se-
quencing (MPS), and long-range PCR with mass spectrometry
have recently been used for novel virus discovery. The XMRV
story demonstrates the potential use of emerging nucleic acid-
based technologies as a powerful tool for evaluation of virus con-
tamination in clinical and biological materials; however, the in-
tensive follow-up highlights the efforts and resources that may be
needed to assess the biological relevance and significance of the
initial detection of a nucleic acid signal in assays that are based on
these technologies. Additionally, the detection of MLV-related se-
quences as a broad contaminant in research reagents demon-
strates the importance of confirming results to determine the or-
igin of a signal using nucleic acid detection assays and to make
efforts to use clean starting materials for an accurate interpreta-
tion of results. This is further highlighted by our findings that
XMRV primer sequences were found in various cell lines, includ-
ing human cell lines, which resulted in the generation of unex-
pected fragments in PCR analyses of various cell lines used for
research or related to the development of biologicals (32). Thus,
although XMRV is not a human retrovirus, it is a “virus of inter-
est” that needs to be considered a potential source of broad con-
tamination with a possible risk of human infections.
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ADDENDUM IN PROOF
PCR analysis of DNAs prepared from whole blood of all of the
animals was found to be negative by testing five replicates of each
monkey at about 2.5 years from animals DBL2(d), DBNP(d),
DBHE(r), and DBLZ(r) and at about 2 years from animals
DBCF(d), DBHT(r), and CF86(r).
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